MedTrace Logo

TheraSphere Japan Pre-Market Study

NCT07377487 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-05-22

No results posted yet for this study

Summary

To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.

Conditions

  • Liver Neoplasms

Interventions

DEVICE

TheraSphere Y-90 glass microsphere

TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Koichiro Yamakado, MD, PhD · Hyogo Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-22
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07377487 on ClinicalTrials.gov